Introduction
Efficient transcription requires the cooperative action of many molecular machines that render the tightly packaged chromatin accessible to RNA synthesis. This process requires covalent histone modifications that are introduced by specialized enzymes. A subgroup of these proteins adds site-specific methyl groups to histones using the catalytic action of a so-called suppressor of variegation, enhancer of zeste, trithorax (SET) domain.
A special subclass of these SET proteins is responsible for the methylation of lysine 4 in histone H3. This modification is characteristically concentrated around the transcription start site of many active genes (Ruthenburg et al., 2007) . The first member of this particular methyltransferase family has been originally discovered because of its involvement in leukemogenesis and hence was accordingly designated as mixed-lineage leukemia (MLL) protein (Krivtsov and Armstrong, 2007) . Later, several other H3K4 methyltransferases (MLL2, MLL3 and MLL4; nomenclature according to Glaser et al., 2006) were found that shared homology with MLL. MLL2 (also sometimes designated as MLL4) is the gene most closely related to MLL. As indicated by the genomic microenvironment, MLL2 arose by a chromosomal duplication during mammalian evolution (FitzGerald and Diaz, 1999) . MLL and MLL2 share the same overall structure and encode essentially identical functional domains (Glaser et al., 2006) , and both proteins reside in macromolecular complexes of nearly identical composition (Dou et al., 2006) .
Despite the high similarity, only MLL has been described to date as a proto-oncogene that can be activated by chromosomal translocations. These events delete 3 0 portions of MLL, including the methyltransferase function and fuse the remaining 5 0 part with a variety of partner genes on other chromosomes. The corresponding chimeric MLL fusion proteins potently transform hematopoietic precursor cells. On a molecular level, MLL fusions inhibit hematopoietic differentiation by enforcing the continued expression of genes that are normally under control of unaltered MLL and that have to be mandatorily downregulated to allow maturation. With regard to hematopoietic development, the Hox homeobox genes such as Hoxa9 and Hoxa7 and their dimerization partner, Meis1, are the most important targets of MLL fusion proteins (Zeisig et al., 2004) . Recent data indicate that several MLL fusion proteins can either stimulate transcriptional elongation (Mueller et al., 2007) , or induce histone arginine methylation (Cheung et al., 2007) with the net effect of target activation. These fusion partner-associated activities are specifically recruited to the cognate targets by the action of the remaining MLL portion. Structure-function analysis identified two separate domains within the truncated MLL portion that are essential for the oncogenic capacity (Slany et al., 1998; Ayton et al., 2004) . At the very N-terminus, MLL contains a menin interaction domain. Menin was originally identified as the product of the tumor suppressor gene multiple endocrine neoplasia. Menin binding is absolutely essential for the function of the fusion protein, and menin is a component of a macromolecular complex that also contains normal MLL (Yokoyama et al., 2005; Caslini et al., 2007) . Further downstream, a CxxC motif in MLL binds to unmethylated CpG DNA dinucleotides (Birke et al., 2002) . Interestingly, the same region has also been described as a potential repression domain that recruits histone deacetylases, and it has been speculated that the CxxC domain might modulate the functional activator/repressor status of MLL and its derivatives (Zeleznik-Le et al., 1994; Xia et al., 2003) . Despite the fact that both regions are highly conserved in MLL2, strikingly MLL2 has never been shown to be involved in leukemogenic fusion proteins.
To study the functional relationship between MLL and MLL2, we wanted to elucidate whether MLL2 also could be converted to a leukemogenic fusion. Furthermore, we wanted to know which structural determinants of MLL and MLL2 might define the differences between the two proteins, if any. These are medically important questions because MLL-induced leukemias are particularly aggressive and undetected MLL2-fusion patients might benefit from an improved molecular diagnostics to allow a more intense therapy. Here, we show through exhaustive swap experiments that MLL2 has lost the intrinsic capability to form transforming fusions because of small differences in the MLL2-CxxC domain. These alterations most likely alter target gene specificity, and therefore this determinant within the MLL protein is a potential 'soft spot' for specific therapies.
Results
MLL and MLL2 are structurally similar but not functionally equivalent An overall sequence alignment between MLL (NM_005933) and MLL2 (NM_014727, also designated as MLL4) showed that the major functional domains of MLL are also conserved in MLL2 (Glaser et al., 2006) . This is true in particular for the N-terminus where not only the domain organization but also the spacing between the respective motifs has been preserved (see Figure 1a for a schematic overview). The menin-binding domain, three AT-hook sequences and the CxxC motif that binds to nonmethylated CpG dinucleotides are all present at similar positions in MLL and in MLL2. The sequence homology is highest within these motifs, as exemplified by the alignment of the CxxC domain of MLL with human and mouse MLL2/Mll2 (Figure 1b) . Almost all residues that are known to contact DNA (Allen et al., 2006) are identical in these proteins, and cross-species conservation reaches a maximum.
To test whether this structural resemblance also extends to function, an artificial Mll2 fusion protein was constructed mimicking the highly transforming mixed lineage leukemia eleven nineteen leukemia (MLLENL) protein found in acute leukemias. As the cDNA of human MLL2 was not available, the mouse Mll2 cDNA (NM_029274, also known as tryptophantryptophan domain (WW) domain-binding protein 7) was used for these experiments. Overall, the human and mouse MLL2 proteins are approximately 90% identical and human as well as murine MLL fusion proteins are equally leukemogenic. Human MLL fusions have been tested extensively in vitro and in vivo in retroviral transduction/transplantation experiments, whereas murine Mll sequences have been joined with fusion partners in knock-in models of MLL (Chen et al., 2008) . Most likely, therefore, differing properties of MLL and Mll2 are a consequence of protein variation and not of species divergence. The oncogenic capability of the respective MLL/Mll2 fusion proteins was assessed by an in vitro transformation assay that measures the capacity to block the differentiation of primary hematopoietic cells (Lavau et al., 1997) . Unexpectedly, and despite appropriate expression, Mll2ENL did not yield a positive readout in these experiments indicating that notwithstanding the structural relatedness, there must be fundamental functional differences between MLL and Mll2 ( Figure 2 ).
The CxxC domain is responsible for the functional divergence of MLLENL and Mll2ENL
To elucidate the motifs in Mll2 that are responsible for the observed functional difference, a series of swap experiments was carried out (Figure 3a) . A set of Mll2/ MLL chimeric fusion proteins was constructed exchanging the C-terminal portion of Mll2 including the CxxC domain by corresponding sequences from MLL. This switch endowed the corresponding Mll2 fusion proteins with a significant transforming activity. Obviously, the menin-binding site and the AT-hook region of Mll2 were sufficiently conserved to replace the function of the corresponding regions of MLL. The proximal limit of the minimal MLL domain necessary to induce a transforming potential in Mll2ENL could be mapped to the N-terminus of the conserved CxxC core motif ( Figure 3a , swaps 1-6). The slight rise in colonyforming capacity that was observed with progressively shorter swap inserts could be explained by an increase of the viral titer that was inversely proportional to the insert size (not shown). The downstream boundary of the minimal necessary MLL unit, however, extended considerably beyond the core CxxC domain, including a 'post-CxxC' region, characterized by a stretch of amino acids with a high frequency of basic residues, but little actual sequence conservation between MLL and Mll2 ( Figure 3a , swaps 7-9, see also Figure 1b ). To exclude the possibility that the transformation potential of Mll2ENL might simply be blocked by Mll2 inhibitory sequences outside the CxxC region, an Mll2ENL construct with an internal deletion upstream of the CxxC motif was tested ( Figure 3a , swap # 10). As this construct did not score positive in the transformation assay, the CxxC domain itself must be responsible for the lack of transformation potential in Mll2ENL. The contributions of the core CxxC and the basic post-CxxC domains were assessed individually in further experi- The CxxC domains of MLL and Mll2 have nearly identical in vitro DNA-binding properties The CxxC domain of MLL has been described as a CpG dinucleotide recognition motif that discriminates against methylated DNA sequences (Birke et al., 2002) . Therefore, it was tested in electrophoretic mobility shift assay (EMSA) experiments whether the functional disparity between MLL and Mll2 might be due to differing DNA-binding properties. For this purpose, glutathione-S-transferase proteins encompassing the core-and post-CxxC moieties of MLL and Mll2 were bacterially expressed and purified ( Figure 4a ). DNA-binding was assessed in mobility shifts with a probe that has been shown to be an efficient substrate for the MLL-CxxC domain (Birke et al., 2002) . This 52-bp oligonucleotides contained six regularly spaced CpG dinucleotides. As controls, oligonucleotides with the same sequence but cytosine exchanged against 5-methyl cytosine ( Figure 4b ) and oligonucleotides of the same overall base composition but with CpG sequences reversed to guanine-cytosine dinucleotides were used (Figure 4c ). Within normal experimental variations, the Mll2-CxxC DNA-binding properties were indistinguishable from MLL-CxxC in these experiments. Like MLL-CxxC, Mll2-CxxC was also dependent on nonmethylated CpG dinucleotides for efficient association with DNA. Therefore, the functional differences between these domains could not be explained by an inherently different DNAbinding mode. Only MLLENL and to a lesser extent swap 3 were able to activate the expression of these three genes that are known to be essential for transformation. In a similar direction, Mll2ENL could not activate a luciferase construct under control of the Hoxa7 promotor (Schreiner et al., 1999) in a transient reporter assay (Figure 5c , left panel). Similar to the results obtained in primary cells, an exchange of the Mll2-CxxC domain against the corresponding MLL moiety rescued a significant part of the transient transactivation activity (Figure 5c , right panel). Transient transactivation and transformation capability was generally correlated with the exception of swap 5 indicating that for optimal transactivation sequences upstream of the core CxxC domain needed to be included. The different target spectrum of Mll2 fusions also translated into an inability to induce a hematopoietic differentiation block. Only MLLENL and swap 3 transduced cells showed signs of a maturation arrest after 5 days of in vitro culture with a high percentage of cells retaining the precursor specific marker c-kit, whereas Mll2ENL-transduced cells rapidly lost this surface molecule (Figure 5d ).
Discussion
In this report, we present evidence that Mll2, the closest homolog of the highly leukemogenic proto-oncoprotein, MLL, cannot be converted to a transforming protein because of an intrinsic functional difference encoded by the structurally conserved CxxC domain. This was unanticipated because MLL and MLL2 not only share major domains, but both proteins are also the members of a macromolecular complex with identical composition. Both MLL and MLL2 are associated with WDR5, RbBP5, HCF1/2, MENIN and ASH2 (Wysocka et al., 2003; Hughes et al., 2004; Yokoyama et al., 2004; Dou et al., 2005) ,and both proteins catalyze the trimethylation of histone H3 at lysine 4 (H3K4) to enable efficient transcriptional initiation. Therefore, it is a long-standing question why MLL is frequently involved in chromosomal translocations creating leukemogenic fusion proteins, whereas MLL2 has never been found in a comparable situation. Rare examples of MLL2 amplification in solid tumors are the only known instances where it is altered in neoplastic disease (Huntsman et al., 1999) . The experiments shown here reveal that even if the MLL2 gene were the target of chromosomal translocations, the resulting fusion protein would not be transforming. Surprisingly, this is due to evolutionary changes in a small domain, which overall and in comparison with the remainder of the protein, shows high sequence conservation. This CxxC domain, a zinccoordinating motif, is present in several proteins where it serves as a module that binds to CpG dinucleotides (Lee et al., 2001) . In MLL as well as in MLL2, it also discriminates against methylation presumably targeting the proteins to active promoters with unmethylated CpG islands. The structure of the CxxC fold has been solved; however, it remains largely enigmatic how a more specific target site selection might be achieved (Allen et al., 2006) . One report describes the recruitment of the MLL2 complex to the b-globin locus by the 'nuclear factor-erythroid derived 2' transcription factor in erythroid cells (Demers et al., 2007) , but it was not determined which component of the complex was responsible for the direct interaction with nuclear factor-erythroid derived 2. In addition to DNA, the region around the CxxC domain also may interact with various repressor proteins. Histone deacetylases 1 and 2, as well as the polycomb repressive complex members BMI-1 and HPC2 coprecipitate in vitro with recombinant portions of MLL that contain the CxxC motif (Xia (Yu et al., 1995; Glaser et al., 2006) . Here, we pinpoint for the first time a functional unit inside these proteins that might be responsible for the observed difference and it might be interesting to see whether swapping solely the CxxC domain indeed converts the identity of the whole protein. In any case, this domain is a rewarding object for further studies, because a closer understanding of its mode of target selection might open the possibility to interfere with the activation of downstream targets by MLL fusion proteins.
Materials and methods

Plasmids and antibodies
All MLL and Mll2 fusion protein derivatives were constructed with an N-terminal flag tag and inserted into the retroviral vector pMSCV (Clontech, Palo Alto, CA, USA). The The CxxC domain of Mll2 precludes oncogenic activation C Bach et al MLLENL sequence was reported by Tkachuk et al. (1992) . The nucleotide sequence of Mll2 is accessible in the database under NM_029274. All Mll2 portions were amplified from a cDNA kindly provided by F Stewart (Dresden, Germany) and the resulting clones were checked by sequencing. For Mll2/MLL swap constructs, a unique ZraI restriction site located at nt 3331 of the Mll2 cDNA sequence was chosen as joining point. For expression and purification of glutathione fusion proteins, the pGEX vector system (GE Healthcare, Munich, Germany) was used. MLL and Mll2 fusions with either GFP or RFP were performed in pEGFP-N1 and pDSRed1-N1 from Clontech (Palo Alto, CA, USA). The dTomato sequence was derived from pLeGO-dTomato (Weber et al., 2008) .
Anti-flag (M2) antibody was from Sigma, (Taufkirchen, Germany) and antibodies for fluorescence-activated cell sorting analysis were purchased from BDBiosciences (San Jose, CA, USA).
MLL fusion protein transformation assay
The transformation capacity of MLL/Mll2 fusion protein derivatives was determined by serial replating assays as reported earlier (Lavau et al., 1997) . In short, hematopoietic progenitor cells from mouse bone marrow were transduced with the respective MLL construct. Normal cells mature and stop proliferation after repeated replating in a semisolid medium, whereas transformed cells experience a block in EMSA, quantitative reverse transcriptase PCR and luciferase assays Electrophoretic mobility shift assay experiments were performed with glutathione-S-transferase fusion proteins containing the CxxC domains of MLL and Mll2 as indicated. The EMSA procedure has been described in detail (Birke et al., 2002) . Quantative reverse transcriptase PCR was performed to determine mRNA levels of Meis1, Hoxa7 and Hoxa9 in a SYBR green-based assay using following primers: Meis1 (primer fw 5 0 -CCTCTGCACTCGCATCAGTAC-3 0 ; primer rev 5 0 -GTTTGGCGAACACCGCTATATC-3 0 ); Hoxa7 (primer fw 5 0 -CCCTTCGCGTCCGGCTATG-3 0 , primer rev 5 0 -GTCTGG CGTCCCCGCTTCC-3 0 ); Hoxa9 (primer fw 5 0 -GCTCTCCTT CGCGGGCTTACC-3 0 , primer rev 5 0 -GGGCATCGCTTCTTC CGAGTG-3 0 ). All samples were normalized to b-actin (primer fw 5 0 -CCAACTGGGACGACATGGAG-3 0 , primer rev 5 0 -CTCGT AGATGGGCACAGTGTG-3 0 ). RNA for these experiments was isolated from primary hematopoietic precursor cells isolated from bone marrow. The cells were transduced with the respective viral construct and expanded for 5 days in methocel medium with cytokines (IL-3, IL-6, GM-CSF 10 ng/ml; SCF 100 ng/ml) under appropriate selection. RNA was isolated with RNeasy kits from Quiagen (Hilden, Germany) according to the instructions of the manufacturer.
Luciferase assays were carried out as described (Schreiner et al., 1999) with REH pre-B cells using a Hoxa7 promoter driven luciferase reporter and pMSCV-MLLENL or pMSCVMll2ENL constructs in varying concentrations as expression plasmids.
